| |
|
|
|
|
|
NervGen Pharma Closes $19.5 Million Private Placement Financing, and Appoints Dr. Adam Rogers to Board of Directors
|
|
Vancouver, BC, July 19, 2022--NervGen Pharma Corp. (TSXV: NGEN) (OTCQX: NGENF), a clinical stage biotech company dedicated to developing a first-in-class neuroreparative drug to treat nervous system damage, announced that it has closed its private placement of 10,150,000 units of the Company at a price of US$1.50 per unit, for aggregate gross proceeds to the Company of $19.5 million (US $15,225,000).
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
News
Events
Tech Careers
Directory
Tech Stocks
T-Net 100
Members
Feedback
About T-Net
Employers
Post Job Listings
Advertise
